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C E L L  B I O L O G Y
A novel landscape of nuclear human CDK2 substrates 
revealed by in situ phosphorylation
Yong Chi1,2, John H. Carter3, Jherek Swanger1, Alexander V. Mazin4, Robert L. Moritz2, Bruce E. Clurman1*
Cyclin-dependent kinase 2 (CDK2) controls cell division and is central to oncogenic signaling. We used an “in 
situ” approach to identify CDK2 substrates within nuclei isolated from cells expressing CDK2 engineered to use 
adenosine 5′-triphosphate analogs. We identified 117 candidate substrates, ~40% of which are known CDK sub-
strates. Previously unknown candidates were validated to be CDK2 substrates, including LSD1, DOT1L, and Rad54. 
The identification of many chromatin-associated proteins may have been facilitated by labeling conditions that 
preserved nuclear architecture and physiologic CDK2 regulation by endogenous cyclins. Candidate substrates 
include proteins that regulate histone modifications, chromatin, transcription, and RNA/DNA metabolism. Many 
of these proteins also coexist in multi-protein complexes, including epigenetic regulators, that may provide new 
links between cell division and other cellular processes mediated by CDK2. In situ phosphorylation thus revealed 
candidate substrates with a high validation rate and should be readily applicable to other nuclear kinases.
INTRODUCTION
Advanced mass spectrometry (MS) and quantitative phospho­
proteomics enable the identification of large sets of protein phospho­
rylation sites to comprehensively identify protein kinase substrates 
(1–4). However, despite many advances, determining which phos­
phorylation sites are direct and physiologic targets of a specific kinase 
remains challenging. Analog­sensitive kinases (AS­kinases) are an im­
portant tool for discovering kinase substrates. AS­kinases contain a 
mutation in a conserved “gatekeeper” residue that normally functions 
to restrict active site access to adenosine 5′­triphosphate (ATP; but 
not other nucleotides) (3, 5–7). Replacing the gatekeeper residue with 
a smaller amino acid renders AS­kinases capable of using bulky ATP 
analogs that cannot be used by normal kinases. By using bulky ATP 
analogs in combination with AS­kinases in various ways, the activity 
of an AS­kinase can be isolated from that of other cellular kinases.
In vitro applications of AS­kinases use ATP analogs to directly 
tag substrates with a label that distinguishes them from other cellular 
phosphoproteins [reviewed in (3, 6)]. However, because ATP analogs 
cannot enter intact cells, these approaches require in vitro conditions 
that can be prone to artifacts. For example, the use of highly active 
recombinant AS­kinases and cell lysates (in which cellular contexts 
are lost) can produce false­positive identifications that may greatly 
increase the experimental work needed to validate candidate sub­
strates. In contrast, in vivo applications of AS­kinases typically 
identify proteins that are differentially phosphorylated in cells treated 
with highly specific AS­kinase inhibitors, sometimes in the context 
of AS mutations engineered into endogenous kinases (3, 6). While 
these methods are not prone to in vitro artifacts, they cannot readily 
distinguish direct substrates from phosphorylations that may be 
indirectly regulated by AS­kinase inhibition because substrates are 
not directly labeled by the AS­kinase.
Cyclin­dependent kinases (CDKs) are holoenzymes consisting 
of catalytic (CDK) and regulatory (cyclin) subunits that regulate 
cellular process by phosphorylating complex substrate networks 
(8, 9). Many mammalian CDKs—including CDK1, CDK2, CDK5, 
CDK7, and CDK9—have proven amenable to AS mutations and have 
been studied using both direct and indirect approaches (10–18). 
Cdk2 is activated by cyclin E and cyclin A. Cyclin E­Cdk2 regulates 
cell cycle re­entry, G1 progression, and S phase entry, whereas 
cyclin A–Cdk2 acts later in the cell cycle, where it coordinates S phase 
progression and functions in G2 and M phase cells. In previous 
work, we developed an in vitro approach using recombinant cyclin 
A/AS­CDK2 and thiophosphate labeling to identify >100 candidate 
cyclin A–CDK2 substrates in human cell lysates (19). The use of a 
thiophospho­ATP analog allowed a biochemical enrichment–based 
strategy and prevented ATP analog hydrolysis in cell lysates. Shokat 
and colleagues (10) also developed a thiophosphate­based method 
to study AS­CDK1 in vitro, which used alternate thiophosphate 
chemistry. These studies revealed candidate substrates common to 
both CDK2 and CDK1 and unique candidates for each kinase. 
However, the extent to which any of these proteins is predominantly 
a CDK1 versus CDK2 substrate in vivo is not known.
Because of its crucial roles in normal and neoplastic signaling, 
we sought to identify high confidence CDK2 substrates using con­
ditions that maintain near­physiologic CDK2 activity and preserve 
nuclear context and architecture. In this approach, termed “in situ 
phosphorylation,” we first stably expressed ectopic AS­CDK2 in 
cells, which is activated by endogenous cyclins and thus subject to 
near­normal regulation. We then isolated nuclei from cells express­
ing either wild­type CDK2 (WT­CDK2) or analog­sensitive CDK2 
(AS­CDK2) and performed in situ substrate thiophosphorylation 
by incubating the nuclei with an ATP­­S analog. These conditions 
allow substrates to be phosphorylated in conditions that better pre­
serve CDK2’s normal subcellular interactions with its substrates. 
We subsequently used biochemical enrichment and MS to identify 
candidate substrates.
We identified ~150 AS­CDK2–specific thiophosphopeptides and 
117 candidate CDK2 substrates. Remarkably, ~43% of these proteins 
are known CDK substrates, indicating that a high proportion of the 
candidates are physiologic CDK2 substrates. Moreover, we found 
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that each of the candidates we tested was directly phosphorylated by 
CDK2 in vitro or in vivo, further supporting the idea that candidates 
identified through in situ phosphorylation contain a high proportion of 
bona fide CDK2 substrates. Many previously unidentified candidates 
are chromatin­ associated proteins with roles in histone modification 
and chromatin remodeling; DNA metabolism, damage, and repair; 
and transcription and RNA metabolism, and whose identification was 
likely allowed by maintaining the nuclear contexts within which 
CDK2 normally functions. In summary, in situ conditions led to the 
efficient and more confident identification of CDK2 substrates. 
These methods should be readily applicable to other nuclear kinases 
with complex substrate networks.
RESULTS
Developing AS-CDK2 cells and substrate 
thiophosphorylation in isolated cell nuclei
We used retroviral transduction to generate pools of human embryonic 
kidney–293 (HEK293) cells that stably express either WT­HACDK2 
or AS­HACDK2 [hemagglutinin (HA) tagged] at levels slightly less 
than endogenous CDK2 (Fig. 1A). A previous study revealed that 
AS­CDK2 has impaired cyclin A binding that prevents AS­CDK2 
from effectively competing with endogenous CDK1 and CDK2 for 
cyclin A binding (12). Accordingly, AS­CDK2 had less kinase activity 
than WT­CDK2, as assayed by immunoprecipitation kinase assays 
using antibodies against the HA­tag (specific to ectopic CDK2), total 
CDK2, or cyclin E (Fig. 1, B and C). To overcome this defect, we 
inhibited endogenous CDK2 by using lentiviruses encoding a short 
hairpin RNA (shRNA) targeting the CDK2 3′ untranslated region 
(3′UTR; which is not present in the retroviral CDK2 complementary 
DNAs), which silenced endogenous CDK2 to almost undetectable 
levels (Fig. 1A). As predicted, endogenous CDK2 knockdown increased 
AS­CDK2 activity, presumably by enhancing cyclin association 
(Fig. 1, B and C). However, AS­HACDK2 activity remained lower 
than WT­HACDK2 activity even after endogenous CDK2 knockdown 
(Fig. 1B). Silencing endogenous CDK2 thus yielded detectable 
AS­CDK2 activity that was somewhat less than endogenous CDK2 
activity, rather than supraphysiologic activity.
Since the cell membrane is impermeable to nucleotides, we isolated 
nuclei using hypotonic methods to help preserve nuclear integrity 
and determined that ATP­­S enters isolated nuclei and that proteins 
could be readily labeled by incubating nuclei with ATP­­S (table S1). 
We then used nuclei isolated from WT­ and AS­HACDK2 cells in 
conjunction with N6­(2­phenylethyl)–ATP­­S (PE–ATP­­S) to 
directly label nuclear CDK2 substrates (Fig. 2A). Cells have high 
concentrations of ATP (>1 mM) that competes with PE–ATP­­S 
for kinase occupancy. We thus included Mn2+ in the in situ kinase 
reaction, which improves thiophosphate labeling by allowing more 
effective competition with cellular ATP (20). Last, CDK2 substrates 
that are already highly phosphorylated by CDK2 in vivo may not 
be additionally labeled by the thiophospho­ATP analog in situ. We 
thus briefly pretreated cells with a CDK inhibitor (roscovitine) before 
harvesting and isolating nuclei to inhibit endogenous CDK2 and allow 
substrate dephosphorylation before labeling in situ (Fig. 2A).
Thiophosphopeptide recovery and identification of high 
confidence nuclear CDK2 substrates
Nuclei were lysed after thiophosphorylation and digested with trypsin, 
and the resultant tryptic peptides containing either thiophosphate 
or cysteine were bound to a disulfide resin (Thiopropyl Sepharose 
6B) as previously described (Fig. 2, B and C) (19)). We developed a 
new method to elute thiophosphopeptides from the disulfide beads 
with dithiothreitol (DTT), which retains the thiophosphate tag 
within the eluted peptides (thereby providing a unique mass signature 
for AS­CDK2 substrates) and allows the elution of cysteine­containing 
thiophosphopeptides. Although DTT elutes a large excess of peptides 
that simply contain cysteine, current MS instruments easily handle 
the additional sample complexity, and these peptides were readily 
excluded from subsequent analyses. Moreover, the mildly acidic 
conditions used favor the binding and elution of thiophospho­
peptides over cysteine­containing peptides (21).
We performed a large­scale experiment, in which four replicates 
of cell nuclei from WT­ or AS­HACDK2 cells were labeled with 
PE–ATP­­S (see Materials and Methods). We identified 4592 
unique peptides, of which 464 were unique thiophosphopeptides 
(about 10% of the total eluted peptides), and almost all (~99%) of 
the remaining peptides contained cysteine (table S2). Among the 
326 unique “stripped” thiophosphopeptides (distinguished only on 
the basis of primary sequence), 166 thiophosphopeptides were 
found only in AS­CDK2 samples, 32 only in control WT­CDK2 
samples, and 128 in both (table S3). Candidate CDK2 substrates 
were defined as containing thiophosphopeptides that (i) were present 
only in AS­CDK2 samples and (ii) have primary sequences that 
contain proline­directed CDK phosphorylation motifs (serine or 
threonine followed by a proline, termed “S/T­P”). Applying these 
criteria, 156 of 166 (93%) of the CDK2­AS–specific thiophospho­
peptides had at least one S/T­P site, which corresponds to 117 
Fig. 1. Characterization of AS-CDK2 activity. (A) HEK293 cells [control (con)] and 
HEK293 cells stably expressing WT-HACDK2 and AS-HACDK2 were transduced with 
lentiviral vectors expressing control or one of two different CDK2 shRNAs (#1 
and #2) for 2 days. Cell lysates were immunoblotted with anti-CDK2 and anti–-tubulin 
(loading control) antibodies. The positions of CDK2 and ectopic HA-CDK2 are in-
dicated. (B and C) Lysates from the above cells were immunoprecipitated (IP) with 
anti-HA (B), anti-CDK2, and anti–cyclin E antibodies (C), and histone H1 kinase 
assays were carried out in the presence of -32P-ATP.
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unique proteins. The Comet search engine localized the presumptive 
thiophosphorylation site to be the proline­directed S/T­P residues 
in 148 of 156 (95%) of the AS­specific S/T­P thiophosphopeptides 
(tables S3 and S4). Most (94%) of these 117 substrates are nuclear 
proteins, and only 33 of 117 had been found in our previous in vitro 
studies. About 95% of the phosphorylation sites carried the full 
CDK consensus motif S/T­P­X­R/K (where X is any amino acid), 
and ~95% of these phosphorylations have been reported in large­
scale in vivo phosphoproteome analyses (22–25). We recovered six 
cysteine­containing thiophosphopeptides representing four unique 
proteins (tables S3 and S4). Fifty of 117 (43%) candidate substrates 
are known CDK substrates, indicating a remarkably high proportion 
of physiologic CDK substrates within the candidate list generated in 
situ (table S4).
In addition to known CDK substrates, we found a novel land­
scape of candidate CDK2 substrates, most of which function within 
key nuclear processes, including cell cycle control, histone modifica­
tion and chromatin organization, DNA replication and repair, tran­
scription, and RNA metabolism (Fig. 3A). The high proportion of 
candidates associated with chromatin modification, DNA metabolism, 
and transcription is likely the result of in situ conditions that pre­
serve cyclin­CDK2 chromatin associations. For example, we identi­
fied 11 proteins that regulate histone modifications as candidate 
substrates, eight of which are previously unknown (DOT1L, JARID2, 
KAT6A, LSD1, MSL1, MSL3, SETDB1, and NSD2) and three of which 
are known CDK substrates (KMT2B, PHF8, and SUV39H1). We also 
found candidates with broader roles in chromatin remodeling (e.g., 
BCOR, BCL11A, DMAP1, INO80E, and SMARCA5) and known 
CDK substrates with chromatin remodeling functions (e.g., BRD4). 
Similarly, we identified many proteins that regulate transcription 
and RNA metabolism, and these include many previously unknown 
candidate CDK2 substrates (see Discussion).
We further interrogated the relationships between the substrates 
in this network by searching protein­protein interaction databases. 
First, we manually curated the known physical interactions between 
all of the substrates with one another by using BioGRID 3.5 (https://
thebiogrid.org) (table S5) (26). We found extensive physical inter­
actions between many of the CDK2 substrates, reinforcing the master 
regulatory roles that CDK2 plays in processes such as cell division 
and DNA repair and replication. Next, we examined whether and 
how candidate substrates coexist within known multiprotein complexes 
by using the Corum database (https://mips.helmholtz­muenchen.de/
corum/) (27). Many known and candidate substrates coexist within 
these defined Corum complexes in both expected and unexpected 
ways, suggesting that CDK2 may globally regulate these complexes 
through phosphorylating multiple subunits thereof (Fig. 3, B and C, 
and see Discussion). One particularly notable finding was the 
co­occurrence of candidate CDK2 substrates in complexes with crucial 
Fig. 2. Schema for identification of CDK2 substrates using an in situ nuclear labeling assay. (A) Scheme for in situ labeling. Asynchronously growing HEK293 cells 
stably expressing WT-CDK2 (AS-CDK2) were pretreated with roscovitine and harvested by trypsinization. Nuclei were isolated as depicted, incubated with PE–ATP--S to 
allow thiophosphate labeling of proteins, and subsequently lysed (see Materials and Methods). (B) Scheme for thiophosphopeptide isolation and identification. Labeled 
nuclear extracts were digested with trypsin. The resulting peptides were incubated with disulfide beads, which capture both thiophosphopeptides and cysteine-containing 
peptides. Beads were eluted with dithiothreitol (DTT), and the eluted peptides were subjected to liquid chromatography coupled to tandem MS to identify the thio-
phosphopeptides. Specific thiophosphopeptide identifications that carried proline-directed phosphorylation motifs and were present in the AS-CDK2 cells but not control 
WT-CDK2 cells were considered as candidate CDK2 substrates. (C) Schematic of thiophosphopeptide and cysteine-containing peptide elution from disulfide beads by DTT.
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epigenetic functions, particularly those that contain both LSD1 and 
the histone deacetylase 1/2 (HDAC1/2) (Fig. 3, D to G, and see 
Discussion). References for each of these specific complexes can be 
found on the Corum website.
In vitro validation of select candidate CDK2 substrates
The high proportion of known CDK substrates found in our screen 
suggested that many candidates may also be bona fide CDK2 sub­
strates. We thus determined whether a group of nine candidates 
(representing proteins that were readily immunoprecipitated from 
transfected cells) were phosphorylated by recombinant cyclin A–CDK2 
in vitro. These include (i) NSD2, a SET­domain histone lysine 
methyltransferase; (ii) DMAP1, a component of the NuA4 histone 
acetyltransferase complex; (iii) LSD1/KDM1A, a histone H3 Lys­4 
demethylase; (iv) DOT1L, a methyltransferase that acts on Lys79 of 
histone H3; (v) BCL11A, a transcription factor (TF) associated with 
chromatin remodeling; (vi) PRPF3, a component of the precatalytic 
spliceosome; (vii) MSL3, a chromatin remodeling protein and 
regulator of histone H3 acetylation; and (viii) GTF3C2, a general TF 
required for RNA polymerase III–mediated transcription. Last, we 
recently validated Rad54 phosphorylation on both T31 and S59 by 
CDK2 in vitro and found that S49 phosphorylation inhibits Rad54’s 
branch migration activity (28).
We immunoprecipitated each of these nine proteins from trans­
fected HEK293 cells and tested their ability to be phosphorylated by 
recombinant cyclin A–CDK2 in vitro using 32P­ATP (Fig. 4). All 
nine of these in situ candidates were validated to be direct CDK2 
substrates in vitro. In the case of DMAP1, it was necessary to elute the 
immunoprecipitated protein for it to be phosphorylated (Fig. 4, C and F), 
whereas the other substrates were readily phosphorylated while bound 
to beads (Fig. 4, A and B). Immunoblots of the immunoprecipitated 
substrates are shown in Fig. 4 (D to F).
In vivo validation of select candidate CDK2 substrates
We next determined whether any of three of these previously un­
known substrates (RAD54, DOT1L, and LSD1) are phosphorylated 
by CDK2 in vivo by either generating phosphosite­specific antibodies or 
using commercial phospho­specific antibodies. Because we identified a 
RAD54 phosphopeptide containing T31 in our substrate screen, we 
generated an anti­Rad54 antibody that detects phosphorylated T31 in 
a phosphatase­ sensitive manner (fig. S1A). The anti­pT31 antibody 
also exhibited a small amount of reactivity against unphosphorylated 
Rad54, which was eliminated when the epitope was deleted (fig. S1B). 
Endogenous RAD54 was hypophosphorylated on T31 in asyn­
chronous cells, but T31 phosphorylation rapidly increased when cells 
were treated with the phosphatase inhibitor okadaic acid, suggesting 
that endogenous Rad54 T31 phosphorylation is highly labile and 
opposed by a phosphatase (fig. S1C). Phospho­T31 was also readily 
detectable on ectopic Rad54 in vivo (without okadaic acid treat­
ment); this was reduced by brief CDK inhibition with roscovitine 
(Fig. 5A) and, conversely, increased by cyclin A–CDK2 overexpression 
(Fig. 5B). Residual Rad54 T31 phosphorylation in roscovitine­treated 
A B C
D E
F G
Fig. 3. Functional categorization of CDK2 candidate substrates. (A) Candidate substrates are grouped based on select gene ontology processes and with manual 
curation. Boldfaced proteins denote known CDK substrates. (B to G) Examples of CDK2 substrates and candidate substrates (green subunits) co-occurring in known 
Corum complexes. The Corum complex identification number is shown in the middle of each depicted complex. The following complexes are shown: (B) BASC complex, 
6 of 12 components depicted; (C) Emerin complex 24, 6 of 6 components depicted; (D) NuRD complex, 6 of 7 components depicted; (E) LSD1 complex, 6 of 14 components 
depicted; (F) XFIM complex, 5 of 5 components depicted; and (G) SNF2h-cohesin-NuRD complex, 6 of 16 components depicted.
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cells likely reflects either incomplete T31 dephosphorylation during 
the brief period of CDK2 inhibition or a roscovitine­insensitive 
kinase that also phosphorylates T31. Because CDK2 directly phos­
phorylates T31, these data are consistent with the idea that CDK2 
directly phosphorylates RAD54 on T31 in vivo, although it is formally 
possible that another T31 kinase is up­regulated by cyclin A–CDK2 
overexpression. Last, because CDK activity is highest in mitosis, we 
studied endogenous Rad54 in cells arrested in prometaphase with 
nocodazole (see flow profiles in fig. S1D) and found high levels 
of T31 phosphorylation that was almost completely inhibited by 
two CDK inhibitors, roscovitine and RO­3306 (a CDK1 inhibitor) 
(Fig. 5C). Thus, endogenous RAD54 is phosphorylated in mitosis 
on T31, likely by CDK2, CDK1, or both. Because we used a pT31­ 
specific antibody, we were unable to assess Rad54 S49 phosphoryl­
ation in vivo.
To study DOT1L, we made a phospho­specific antibody against 
its pS297 epitope. We chose S297 instead of the S775 site identified 
in our screen because S297 is a CDK consensus site that falls within 
a conserved catalytic domain of DOT1L. We found that the anti­
body was specific for S297 (fig. S1F) and that coexpression of 
DOT1L with cyclin A–CDK2 strongly stimulated DOT1L S297 
phosphorylation (Fig. 5D). We were unable to detect endogenous 
DOT1L protein and thus could not study its phosphorylation.
Last, we performed similar validation experiments for LSD1. 
Although we failed to make a phospho­specific antibody against T59 
(the site we identified by MS), a commercial phospho­T/P antibody 
specifically detected T59 phosphorylation of LSD1 in vitro, as 
shown by the strong LSD1 phosphorylation after cyclin A–CDK2 
treatment and the lack of detectable phosphorylation of an LSD1 
T59A mutant (fig. S1E). Using this phospho­T/P antibody, we found 
that endogenous LSD1 is phosphorylated in vivo and strongly stimu­
lated by cyclin A–CDK2, suggesting that cyclin A–CDK2 phosphorylates 
LSD1 on T59 in vivo (Fig. 5E). Endogenous LSD1 was also strongly 
phosphorylated in nocodazole­treated cells in a roscovitine­dependent 
and RO­3306–dependent manner (Fig. 5F). This phosphorylation 
was completely eliminated when an ectopic T59A LSD1 mutant was 
compared with ectopic WT LSD1, indicating that pT59 is also 
recognized by the pT/P antibody in vivo (Fig. 5G). We also studied 
synchronized cells to determine whether LSD1 T59 phosphoryl­
ation exhibited cell cycle regulation. By following cells arrested in 
early S phase by a double thymidine block and release, we found 
that T59 phosphorylation was lowest in G1 phase, begins to rise in 
S phase, and peaks in G2­M phase (Fig. 5, H and I). This pattern is 
highly reflective of CDK2 activity during the cell cycle, although we 
were unable to directly test this because CDK2 inhibition prevents 
cell cycle progression after cell synchronization and release. In 
Fig. 4. Validation of select CDK2 candidate substrates in vitro. (A) FLAG-tagged PRPF3, Myc-tagged BCL11A, and HA-tagged MSL3 and GTF3C2 were expressed in HEK293 
cells and immunoprecipitated from cell lysate using antibodies against the tag. Washed immunoprecipitates were phosphorylated using purified cyclin A–CDK2 (or no 
kinase control) in the presence of 32P-ATP and detected by autoradiography. Histone H1 kinase assay was used as control. oe, overexposure. Lane 9 was empty. Asterisk (*) 
marks the expected band of the substrates. (B) FLAG-tagged NSD2, LSD1, and DOT1L were analyzed as in (A). (C) FLAG-tagged DMAP1 was analyzed as in (A), except that the 
washed immunoprecipitates were first eluted with a FLAG peptide and fractions of the eluate were used in the kinase assay. Lane 2 was empty. (D and E) Immunoblots (IB) 
of a fraction of the corresponding immunoprecipitates shown in (A) and (B) using the antibodies against the tag. In (D), lanes 2 and 4 were empty. (F) Immunoblot of the gel 
in (C) after autoradiography using FLAG antibody.
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summary, these data support that Rad54, DOT1L, and LSD1 are 
in vivo substrates of CDK2.
DISCUSSION
CDK2 has critical roles in cell division, DNA replication, DNA 
damage and repair, and cell cycle checkpoints. Moreover, CDK2 
mediates many oncogenic pathways and responses to anti­neoplastic 
agents. While many CDK2 substrates in these pathways have been 
identified, crucial aspects of normal and neoplastic CDK2 function 
remain unknown. We thus developed in situ phosphorylation to enable 
future mechanistic studies by identifying previously unknown physio­
logic substrates. In addition to many known CDK substrates, we identi­
fied ~70 previously undiscovered candidate substrates. Validation studies 
of a set of nine candidates confirmed that each was a CDK2 substrate, 
suggesting that many (or most) candidates will be found to be bona 
fide substrates. In situ phosphorylation identified a very different 
set of CDK2 substrates from those found in vitro, including many 
chromatin­associated proteins that we speculate were discovered 
because in situ kinase reactions are performed under conditions in 
which the normal subcellular relationships between CDK2 and its 
nuclear substrates are preserved.
One particularly interesting set of candidates includes enzymes that 
modify histones and chromatin. CDK2 affects histone abundance 
Fig. 5. CDK2-dependent phosphorylation of RAD54, DOT1L, and LSD1 in vivo and cell cycle regulation of LSD1 T59 phosphorylation. (A) Myc-tagged RAD54 WT 
and T31A mutant were immunoprecipitated from transfected HEK293 cells and immunoblotted for T31 phosphorylation and total RAD54 protein. Roscovitine (Rosc) was 
added 2 hours before harvest. Untransfected cells, control. Arrow denotes endogenous RAD54. (B) HEK293 cells were cotransfected with myc-tagged RAD54 and myc-
tagged cyclin A–HACDK2 or vector control. RAD54 was immunoprecipitated and immunoblotted for T31 phosphorylation and total RAD54 protein (top), and the cell 
lysates were immunoblotted for cyclin A and CDK2 expression (bottom). -Tubulin–loading control. (C) HEK293 cells were treated with nocodazole (Noc) for 17 hours, and 
endogenous RAD54 was immunoprecipitated and immunoblotted for T31 phosphorylation and for total RAD54 protein. Roscovitine or RO-3306 was added 1 hour before 
harvest. “Noc-” indicates asynchronous cells. (D) FLAG-tagged DOT1L was analyzed as in (B). DOT1L phosphorylation was detected using an anti–phospho-S297 DOT1L 
antibody. Untransfected cells, control. (E) HEK293 cells were transfected with myc–cyclin A and HA-CDK2 or vector control. Endogenous LSD1 was immunoprecipitated 
and immunoblotted for T59 phosphorylation using anti–phospho-TP antibody and also for total LSD1 (top). Cell lysates were immunoblotted for cyclin A and CDK2 
expression (bottom). -Tubulin, loading control. (F) Endogenous LSD1 was analyzed as in (C). (G) FLAG-tagged LSD1 WT and T59A mutant were immunoprecipitated from 
transfected HEK293 cells that were treated with nocodazole for 17 hours and immunoblotted for T59 phosphorylation and total LSD1. (H) HEK293 cells were synchronized 
at the G1-S boundary by double thymidine block and released. Cells were harvested at indicated times. Endogenous LSD1 was immunoprecipitated and immunoblotted 
for T59 phosphorylation using anti–phospho-TP antibody and also for total LSD1 (top). Cell lysates were immunoblotted for LSD1 and -tubulin (bottom). (I) Cell cycle 
profiles at the indicated times using flow cytometry.
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and activity in several ways: (i) by direct histone phosphorylation 
(29), (ii) by regulating histone transcription through NPAT phos­
phorylation (30), and (iii) through phosphorylation of histone­ 
modifying enzymes, such as EZH2, which controls epigenetic gene 
silencing (31). Here, we identify several candidate CDK2 substrates 
with important roles in histone modification (DOT1L, JARID2, 
KAT6A, LSD1, MSL1, MSL3, SETDB1, and NSD2) or broader roles 
in chromatin remodeling (e.g., BCOR, DMAP1, INO80E, and 
SMARCA5).
Another interesting group of candidate substrates is composed 
of transcriptional regulators and TFs, which include proteins with 
roles in cancer (e.g., BCL11A and AF9) and more general transcrip­
tional functions (e.g., GTF2I). We also found several proteins 
with roles in splicing and RNA metabolism (e.g., PRP3, PRP16/
DHX38, and SRRM2). Again, we speculate that CDK2­mediated 
phosphorylation of these transcriptional and mRNA regulators 
may thus provide important mechanisms linking control of cell 
division with gene expression. Last, while CDK2’s roles in DNA 
replication, damage, and repair are well known, we identified previ­
ously undiscovered putative substrates with important roles within 
these well­studied pathways, including RIF1, RAD54, and XRCC1. 
Future studies are needed not only to validate these candidates 
but also to understand how they are regulated by CDK2­mediated 
phosphorylation during the cell cycle.
As noted above, many of the CDK2 substrates we found coexist 
within known complexes, suggesting that CDK2 may regulate these 
complexes by targeting multiple components for phosphorylation, 
perhaps within the context of the complexes themselves. For example, 
while many cell cycle and DNA repair proteins are found in com­
plexes with canonical functions (e.g., BASC complex; Fig. 3B), these 
proteins are also found in complexes with unknown functions, such 
as the Emerin 24 complex (Fig. 3C). Studies of these atypical com­
plexes may reveal new functions for CDK2.
One particularly interesting finding involves the presence of 
multiple CDK2 substrates within complexes with epigenetic func­
tions, many of which contain both the LSD1 histone demethylase 
and the HDAC1/2 histone deacetylases. These complexes regulate 
gene expression through coordinated chromatin modification, in­
cluding histone demethylation and acetylation. In addition to LSD1 
and HDACs, these complexes also contain unique subunits, which 
include previously undiscovered CDK2 substrates, including RREB1, 
MTA1, SMARCA5, ZMYM3, and GTF2I (Fig. 3, D to G). The pres­
ence of multiple CDK2 substrates within these epigenetic regulators 
suggests that CDK2 may directly affect their function via direct 
phosphorylation of these components, perhaps in cell cycle–specific 
ways. There are numerous additional examples of multiple CDK 
substrates contained within complexes that regulate transcription, 
cell division, ribosomal biogenesis, and other cellular processes. We 
speculate that these substrates link the control of cell division with 
the regulation of gene expression at many levels via their phosphoryl­
ation by CDK2.
Validation work is a bottleneck for all proteomic screens, and it 
is highly desirable to improve the ability of these screens to identify 
physiologic substrates. While we initially attempted to label CDK2 
substrates in living cells using different delivery systems, we were 
unable to deliver ATP­­S analogs into live cells in an efficient and 
noninvasive way. We thus sought to preserve nuclear contexts while 
also allowing direct substrate labeling by performing in situ kinase 
assays in isolated nuclei. This in situ approach has notable advantages, 
including (i) maintenance of nuclear structures and the cellular 
contexts within which CDKs normally function, (ii) near­physiologic 
CDK2­AS abundance and activity, and (iii) maintaining thio­
phosphate signatures after elution, which allows more confident 
identification of peptides phosphorylated by the AS­kinase. As a 
result, the list of candidate CDK2 substrates was highly enriched for 
known CDK substrates, and all of the candidates that we studied 
were validated to be phosphorylated by CDK2. We thus believe that 
it is likely that many (or most) of the candidates that remain untested 
will prove to be bona fide CDK2 substrates.
Although we confirmed a high rate of validation, several factors 
may still contribute to false­positive substrate identifications. For 
example, nearly half of the thiophosphopeptides we identified were 
found in both CDK­AS and CDK2­WT kinase assays, indicating 
that some AS­CDK2–independent background labeling occurs, with 
a signal­to­noise ratio of about 1 (table S3). This background likely 
results from cellular kinases known to use bulky ATP analogs (32). 
While it is also possible that PE–ATP­­S was hydrolyzed during 
the kinase reaction (thereby generating ATP­­S that can be used by 
many cellular kinases), we previously found that ATP­­S and PE–
ATP­­S are stable in whole­cell lysates, and this is likely also true in 
isolated nuclei (19). Despite this background, by requiring that 
thiophosphopeptides contain S/T­P motifs to be considered as sub­
strates, the vast majority of background thiophosphopeptides were 
eliminated from subsequent analyses. The few thiophosphopeptides 
present in the “WT­CDK2–only” samples indicates that our MS 
analyses did not reach saturation with respect to peptide identifica­
tions. Thus, some “AS­specific” candidate substrates may drop out 
if they are found in WT­CDK samples with additional replicates. 
However, thus far, our validations have not revealed many false­ 
positive identifications. Last, because our methods require isolating 
intact nuclei, we could only identify CDK2 substrates in inter­
phase cells. This limitation may explain why we did not detect elon­
gation factor 2, which is a cytoplasmic protein phosphorylated by 
CDK2 only in mitosis (33).
In conclusion, we describe an in situ implementation of AS­CDK2 
for substrate discovery that allows CDK2 to phosphorylate its sub­
strates under near­physiologic conditions. We also developed method­
ological advances to identify candidate AS­CDK2 substrates more 
definitively and comprehensively. As a result, we found a high per­
centage of known CDK substrates and a high rate of validation for 
previously undiscovered candidates. Moreover, the enrichment for 
chromatin­associated proteins with important roles in processes such 
as gene expression and DNA and RNA metabolism suggests that 
in situ conditions may allow new types of substrates to be identified 
for CDKs and other nuclear kinases that function within specific 
nuclear contexts. These methods should be readily adaptable to study 
other nuclear kinases that are amenable to AS mutations.
MATERIALS AND METHODS
Experimental design
The objectives of this study were to develop a near physiologic envi­
ronment for substrate phosphorylation by AS­CDK2. The primary 
study design provided two mechanisms to accomplish this goal. 
The first was to stably express AS­CDK2 at normal abundance and 
to allow the exogenous AS­CDK2 to be activated by endogenous 
cyclins, which are rate limiting for CDK2 activation. The second 
was to isolate nuclei and allow substrates to be phosphorylated 
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by AS­CDK2 in a nearly normal nuclear environment. We used 
substrate thiophosphorylation for several reasons: (i) We previously 
have characterized the ability of AS­CDK2 to use and hydrolyse 
ATP­­S, (ii) we previously developed efficient biochemical methods 
to enrich and identify thiophosphopeptides by MS, and (iii) thio­
phosphate allows AS­CDK2 substrates to be easily distinguished from 
other cellular phosphopeptides. As shown in Fig. 2, the overall 
design consisted of the following steps: (i) stable expression of AS­
CDK2 in HEK293A cells, (ii) inhibition of endogenous CDK2 by 
shRNA, (iii) treatment of cells with roscovitine to inhibit endoge­
nous CDKs, (iv) isolation of nuclei and incubation with PE–ATP­­S, 
(v) thiophosphopeptide enrichment and identification by MS, and 
(vi) substrate validation in vitro and in vivo.
Cell culture, transfection, retroviral transduction,  
and drug treatments
The HEK293 was obtained from the American Type Culture Col­
lection, tested for mycoplasma and genetically authenticated during 
the course of this study. HEK293 cells were cultured in Dulbecco’s 
modified Eagle’s medium (11965­092, Gibco), which was supplemented 
with 10% (v/v) fetal bovine serum (10437­028, Gibco), penicillin 
(100 U/ml), and streptomycin (100 g/ml; 15140­122, Gibco). 
Transient transfections were carried out using calcium phosphate. 
HEK293 cells stably expressing C­terminally HA­tagged WT­CDK2 
or CDK2­F80A (AS­CDK2) were generated via retroviral transduc­
tion using a pBabe­based vector (puromycin) as previously described 
(34). For CDK2 knockdown via small hairpin RNA, cells were 
transduced with lentiviruses encoding nontargeting control shRNA 
or two different shRNAs directed to noncoding regions of CDK2 
mRNA (see below). Cells were harvested 2 days after infection without 
selection, and shRNA expression was confirmed by green fluorescent 
protein coexpression. Nocodazole (M1404, Sigma­Aldrich) was used 
at 40 ng/ml, for 17 hours, roscovitine (R7772, Sigma­Aldrich) was used 
at 25 M for 1 to 2 hours where indicated, and RO­3306 (sc­358700; 
Santa Cruz Biotechnology) was used at 1 M for 1 hour. Okadaic acid 
(O­2220, LC Laboratories) was used at 200 nM for 90 min.
Antibodies, plasmids, enzymes, and other reagents
The following antibodies were used: Myc tag (1:5; 9E10 hybridoma 
supernatant, prepared in house), HA­tag (12CA5 hybridoma super­
natant; prepared in­house), FLAG M2 (1:4000; F1804, Sigma­Aldrich), 
CDK2 (1:1000; D­12, sc­6248, Santa Cruz Biotechnology), cyclin A 
(1:1000; gift from J. Roberts, Fred Hutchinson Cancer Research 
Center), cyclin E (1:1000; HE111, sc­248, Santa Cruz Biotechnology), 
­tubulin (1:1000; sc­17787; Santa Cruz Biotechnology), RAD54 
(1:1000; F­11, sc­374598, Santa Cruz Biotechnology), LSD1 (1:5000; 
A300­215A, Bethyl Laboratories), DOT1L (1:2000; A300­953A, Bethyl 
Laboratories), and phospho­T/P (1:1000; 9391S; Cell Signaling 
Technology). Phospho­T31 RAD54 and phospho­S297 DOT1L 
antibodies were custom made by Yenzym Antibodies (San Francisco), 
raised against the synthetic phosphopeptides CEDWQPGLV­ pT­
PRKRK (RAD54) and CMRVVEL­pS­PLKGSVS (DOT1L).
Substrate expression plasmids were obtained as follows: FLAG­
DMAP1 (C. Kim, Hanyang University), FLAG­NSD2 (J. Licht, 
University of Florida), HA­MSL3 (J. Cotes, Laval University), 
HA­GTF3C2 (R. White, University of York), FLAG­PRPF3 (S. M. 
Iguchi­Ariga, Hokkaido University), and N­terminal FLAG­DOT1L 
and C­terminal HA­DOT1L (Y. Zhang, Harvard). RAD54 was cloned 
into the pCS2+ vector with a C­terminal 5× myc tag. The deleted 
sequence for myc­RAD54­T31A8 was EDWQPGLV. N­terminal 
3× FLAG­tagged LSD1 was cloned into a pCS2+ vector. BCL11A 
was cloned into the pCS2+ 5myc vector. Cyclin A and CDK2 expres­
sion plasmids were pCS2+ 6 myc–cyclinA (gift from J. Roberts, Fred 
Hutchinson Cancer Research Center) and pCMV­CDK2HA (gift 
from S. van den Heuvel, Utrecht University, The Netherlands), re­
spectively. All mutants were generated by site­directed mutagenesis 
using the QuikChange method (Stratagene) and sequenced. Lenti­
viral plasmids using the pGIPZ vector were purchased onsite, 
and the CDK2 3′UTR targeting sequences of the two shRNAs used 
were AGGATGAACAATTATATTT (#1) and AGGTTATATC­
CAATAGTAG (#2). Lambda protein phosphatase (P0753S) and 
recombinant cyclin A–CDK2 were purchased from New England 
Biolabs. Recombinant glutathione S­transferase (GST)–cyclin E–CDK2 
(33) and GST­Rb (19) were prepared in house. ATP­­S was pur­
chased from Millipore Sigma (catalog no. 119120). PE–ATP­­S 
was purchased from BIOLOG Life Sciences Institute (catalog no. 
P026, Bremen, Germany).
Immunoblotting, immunoprecipitation, kinase assays,  
cell synchronization, and flow cytometry
Immunoblotting, Immunoprecipitation, kinase assays, and flow 
cytometry were performed as described (34). Images of full gels for 
each figure are shown in fig. S2. For DMAP1 kinase assay, DMAP1 
was first eluted from immunoprecipitates with FLAG peptide 
(150 g/ml; F4799, Millipore Sigma) and concentrated using a 
MicroCon­30 (MRCF0R030, Millipore Sigma­Aldrich). For cell cycle 
analysis of LSD1 phosphorylation, HEK293 cells were first synchro­
nized by double thymidine block. Briefly, cells were treated with 2 mM 
thymidine (T9250, Millipore Sigma­Aldrich) for 16 hours, washed 
once with fresh medium, and released into fresh medium supplemented 
with 24 M 2′­deoxycytidine (951­77­9, Acros Organics) for 8.5 hours. 
Cells were then washed once with fresh medium and treated again 
with 2 mM thymidine for 18 hours before releasing into fresh medium 
containing 2′­deoxycytidine. Cells were harvested by trypsinization 
at various times up to 25 hours, and a fraction of the cells were fixed 
for flow cytometry analysis.
Cell nuclei isolation and in situ kinase assay
HEK293 cells stably expressing WT­CDK2 or AS­CDK2 were grown 
on eight 15­cm plates (2 days after infection by CDK2 shRNA lenti­
virus) to ~80 to 90% confluence (~2 × 107 cells per plate), treated 
with roscovitine for 1 hour, and harvested in four replicates (two plates 
per cell pellet) by trypsinization, and washed once with cold 
phosphate­buffered saline buffer. Each cell pellet (total of eight) was 
washed twice by resuspending the cells in 1 ml of cold hypotonic 
lysis buffer 1 [10 mM Hepes (pH 7.4), 10 mM KCl, and 2 mM 
MgCl2] followed by centrifugation in a microcentrifuge (2000 rpm, 
1 min). Cells were resuspended again in 1 ml of hypotonic lysis 
buffer 1 and incubated on ice for 15 min. Swollen cells were lysed by 
pipetting up and down five to seven times using a 1­ml syringe with 
26­gauge needle (305111, Becton, Dickinson and Company). Cell 
lysis and intact cell nuclei were verified by staining a small aliquot 
with trypan blue (T10282, Life Technologies). The slurry was slowly 
added to the surface of 6 ml of cold hypotonic lysis buffer 1 contain­
ing 30% sucrose (w/v) in a 15­ml Falcon tube. After centrifugation 
in a tabletop centrifuge at 1000g for 10 min, the buffer above the 
nuclei pellet was removed, and the pellet was washed three times by 
resuspending it in 1 ml of cold hypotonic lysis buffer 1 followed by 
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centrifugation in a microcentrifuge (3000 rpm, 1 min). The nuclei 
preparation was checked again by staining with trypan blue and 
microscope examination. The final nuclei pellet was resuspended in 
1.5× volume of hypotonic lysis buffer 1 containing PE–ATP­
­S (final concentration of 0.5 mM) and MnCl2 (final concentration 
of 0.5 mM final) and incubated at 30°C for 30 min. The nuclei slurry 
was occasionally mixed by tapping during the course of the reaction. 
After the reaction, the nuclei mix was briefly centrifuged (3000 rpm, 
15 s) to remove most of the supernatant, and the pellet was flash­frozen 
in liquid nitrogen and stored or processed as described below. ATP­
­S labeling was done similarly starting with two 15­cm plates of 
WT­CDK2 cells and labeled at a final concentration of 0.5 mM.
Purification of thiophosphorylated peptides
The frozen nuclei pellet was resuspended in 0.4 ml of hypotonic 
lysis buffer 2 [30 mM Hepes (pH 7.4), 10 mM EDTA, and benzonase 
(25 U/ml; 70746, Millipore Sigma)]. After incubation on ice for 30 
min, Tween­20 was added to a final concentration of 0.1%, and the 
sample was sonicated using 20× 1­s pulses. Nuclei debris was pel­
leted by centrifugation at 20,000g for 10 min. The supernatant was 
digested with sequencing grade modified trypsin (Promega) at 1:20 
ratio (w/w), and thiophosphopeptides from the peptide mixture were 
purified by binding to 40 l of disulfide beads Thiopropyl Sepharose 6B 
(17042001, GE Healthcare) at pH 4.0 as previously described (19). 
Washed beads were eluted with 30 l of 25 mM DTT (pH ~4 without 
buffering) in 5% acetonitrile/95% H2O at room temperature for 
30 min. The eluate was acidified with tris(2­carboxyethyl)phosphine 
and formic acid to a final concentration of 5 mM and 0.1%, respec­
tively, and analyzed directly by MS.
MS analysis and database search
Phosphopeptides samples were analyzed by Nanoflow liquid chroma­
tography (NanoLC) and electrospray ionization tandem MS (MS/MS) 
using an LTQ­Orbitrap mass spectrometer (Thermo Fisher Scientific) 
interfaced with an Agilent 1100 Nano Pump with electronically 
controlled split flow. For ATP­­S labeling, one sample was analyzed 
in duplicate MS runs, and for PE­ATP­­S labeling, eight samples 
(four WT­CDK2 and four AS­CDK2) were analyzed in duplicate 
MS runs (16 MS runs in total). Peptides were loaded in sequence 
onto a 75 m (inner diameter) by 15 cm C18 microcapillary col­
umn, packed in­house with Magic C18 AQ 5­m resin (Michrom 
Bioresources), and resolved by a nonlinear gradient of 5 to 28% 
acetonitrile containing 0.1% formic acid at a flow rate of 300 nl/min 
over the course of 80 min. Each survey scan in the Orbitrap was 
followed by MS/MS scans of the top nine most intense precursor ions 
in the linear ion trap. Tandem spectra acquired were searched against 
a human Uniprot database (downloaded January 2015) with target decoy 
using the Comet algorithm (version 2014.02) (35). Peptide search param­
eters included precursor mass tolerance of 20 parts per million, one 
tryptic end for peptide, and differential mass modification to methionine 
(+15.999) due to oxidation and serine and threonine (+96.0329) 
due to thiophosphorylation. Search results were filtered using Trans 
Proteomic Pipeline (36) with a minimal iProphet (37) score of 
0.75 and corresponding peptide false discovery rate (FDR) between 
0.5 to 1%.
Functional enrichment analysis of CDK2 substrates
A network made up of the candidate substrates were created by 
manually inputting the list into the STRING protein query within 
Cytoscape (38, 39) and analyzed using the STRING functional en­
richment tool with an enrichment FDR value cutoff of 0.05. Select 
enriched functional categories were generated on the basis of the 
Gene Ontology process category.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/16/eaaz9899/DC1
View/request a protocol for this paper from Bio-protocol.
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